These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
403 related articles for article (PubMed ID: 25329202)
1. Sofosbuvir-based treatment regimens for chronic, genotype 1 hepatitis C virus infection in U.S. incarcerated populations: a cost-effectiveness analysis. Liu S; Watcha D; Holodniy M; Goldhaber-Fiebert JD Ann Intern Med; 2014 Oct; 161(8):546-53. PubMed ID: 25329202 [TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of novel regimens for the treatment of hepatitis C virus. Najafzadeh M; Andersson K; Shrank WH; Krumme AA; Matlin OS; Brennan T; Avorn J; Choudhry NK Ann Intern Med; 2015 Mar; 162(6):407-19. PubMed ID: 25775313 [TBL] [Abstract][Full Text] [Related]
3. Cost-Effectiveness Modelling of Sofosbuvir-Containing Regimens for Chronic Genotype 5 Hepatitis C Virus Infection in South Africa. Fraser I; Burger J; Lubbe M; Dranitsaris G; Sonderup M; Stander T Pharmacoeconomics; 2016 Apr; 34(4):403-17. PubMed ID: 26666639 [TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States. Chhatwal J; Kanwal F; Roberts MS; Dunn MA Ann Intern Med; 2015 Mar; 162(6):397-406. PubMed ID: 25775312 [TBL] [Abstract][Full Text] [Related]
5. The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection. Linas BP; Barter DM; Morgan JR; Pho MT; Leff JA; Schackman BR; Horsburgh CR; Assoumou SA; Salomon JA; Weinstein MC; Freedberg KA; Kim AY Ann Intern Med; 2015 May; 162(9):619-29. PubMed ID: 25820703 [TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection. Saab S; Gordon SC; Park H; Sulkowski M; Ahmed A; Younossi Z Aliment Pharmacol Ther; 2014 Sep; 40(6):657-75. PubMed ID: 25065960 [TBL] [Abstract][Full Text] [Related]
7. The cost-effectiveness, health benefits, and financial costs of new antiviral treatments for hepatitis C virus. Rein DB; Wittenborn JS; Smith BD; Liffmann DK; Ward JW Clin Infect Dis; 2015 Jul; 61(2):157-68. PubMed ID: 25778747 [TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of sofosbuvir-based treatments for chronic hepatitis C in the US. Zhang S; Bastian ND; Griffin PM BMC Gastroenterol; 2015 Aug; 15():98. PubMed ID: 26239358 [TBL] [Abstract][Full Text] [Related]
9. Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon-ineligible/intolerant individuals. Hagan LM; Sulkowski MS; Schinazi RF Hepatology; 2014 Jul; 60(1):37-45. PubMed ID: 24677184 [TBL] [Abstract][Full Text] [Related]
10. Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study. Ferrante SA; Chhatwal J; Brass CA; El Khoury AC; Poordad F; Bronowicki JP; Elbasha EH BMC Infect Dis; 2013 Apr; 13():190. PubMed ID: 23621902 [TBL] [Abstract][Full Text] [Related]
11. Boceprevir for Chronic Genotype 1 Hepatitis C Virus in the Current Health Care Setting in Greece: A Cost-effectiveness Analysis. Athanasakis K; Ferrante SA; Kyriopoulos II; Petrakis I; Hill M; Retsa MP; Kyriopoulos J Clin Ther; 2015 Jul; 37(7):1529-40. PubMed ID: 26031617 [TBL] [Abstract][Full Text] [Related]
12. Cost-Effectiveness of Genotype 1 Chronic Hepatitis C Virus Treatments in Patients Coinfected with Human Immunodeficiency Virus in the United States. Saab S; Virabhak S; Parisé H; Johnson S; Wang A; Misurski D; Gonzalez YS; Juday T Adv Ther; 2016 Aug; 33(8):1316-30. PubMed ID: 27342742 [TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of boceprevir for the treatment of chronic hepatitis C virus genotype 1 infection in Portugal. Elbasha EH; Chhatwal J; Ferrante SA; El Khoury AC; Laires PA Appl Health Econ Health Policy; 2013 Feb; 11(1):65-78. PubMed ID: 23355388 [TBL] [Abstract][Full Text] [Related]
14. Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation. Hartwell D; Jones J; Baxter L; Shepherd J Health Technol Assess; 2011 Apr; 15(17):i-xii, 1-210. PubMed ID: 21473834 [TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of sofosbuvir plus ribavirin with or without pegylated interferon for the treatment of chronic hepatitis C in Italy. Cure S; Guerra I; Cammà C; Craxì A; Carosi G J Med Econ; 2015; 18(9):678-90. PubMed ID: 25891129 [TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection. Younossi ZM; Park H; Saab S; Ahmed A; Dieterich D; Gordon SC Aliment Pharmacol Ther; 2015 Mar; 41(6):544-63. PubMed ID: 25619871 [TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. Salomon JA; Weinstein MC; Hammitt JK; Goldie SJ JAMA; 2003 Jul; 290(2):228-37. PubMed ID: 12851278 [TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of Early Treatment of Hepatitis C Virus Genotype 1 by Stage of Liver Fibrosis in a US Treatment-Naive Population. Chahal HS; Marseille EA; Tice JA; Pearson SD; Ollendorf DA; Fox RK; Kahn JG JAMA Intern Med; 2016 Jan; 176(1):65-73. PubMed ID: 26595724 [TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of Oral Regimens for Adolescents With Chronic Hepatitis C Virus Infection. Zhou H; Lu Y; Wu B; Che D Pediatr Infect Dis J; 2020 Jun; 39(6):e59-e65. PubMed ID: 32345829 [TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C. Petta S; Cabibbo G; Enea M; Macaluso FS; Plaia A; Bruno R; Gasbarrini A; Craxì A; Cammà C; Hepatology; 2014 May; 59(5):1692-705. PubMed ID: 24691835 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]